A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This retrospective, multi-centre, observational study will assess the daily practice patterns and outcomes of the management of rheumatoid arthritis in patients treated with RoActemra/Actemra (tocilizumab). No actual patient will be enrolled in this study; data will be collected from medical records.
Retrospective, Multi-center, Observational Study of Daily Practice Patterns and Outcomes of the Management of Rheumatoid Arthritis Patients Without Documented Erosions Treated With RoACTEMRA in Belgium
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Retrospective survey of medical records from patients with moderate to severe rheumatoid arthritis treated with RoActemra/Actemra (tocilizumab) who did not have documented erosions at the start of RoACTEMRA treatment .
Adult patients, >=18 years of age
Diagnosed with rheumatoid arthritis and moderate to severe disease activity defined as a DAS28 >=5.1
Inadequate responder to at least 2 non-biological DMARDs
Absence of documented erosions at start of RoActemra/Actemra treatment
Received RoActemra/Actemra treatment for at least 6 months
Availability of data from at least the RoActemra/Actemra treatment initiation visit and the 6 months visit
Contraindications for treatment with RoActemra/Actemra